Incyte (NAS:INCY) Construction In Progress

: $225 Mil (As of Sep. 2022)

View and export this data going back to 1993. Start your Free Trial

Incyte's quarterly construction in progress declined from Mar. 2022 ($227 Mil) to Jun. 2022 ($227 Mil) and declined from Jun. 2022 ($227 Mil) to Sep. 2022 ($225 Mil).

Incyte's annual construction in progress increased from Dec. 2019 ($116 Mil) to Dec. 2020 ($258 Mil) but then declined from Dec. 2020 ($258 Mil) to Dec. 2021 ($220 Mil).

Incyte Construction In Progress Historical Data

The historical data trend for Incyte's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Construction In Progress

11.37

65.58

116.39

257.93

220.05

Incyte Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Construction In Progress																343.69	220.05	227.34	226.67	225.44

Incyte Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Incyte (NAS:INCY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (NAS:INCY) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

INCY:Mexico 0J9P:UK ICY:Germany ICY:Germany I1NC34:Brazil INCY:Austria

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Executives

Tray Thomas	officer: Principal Accounting Officer	C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Brawley Otis W	director	5203 BRISTOL INDUSTRIAL WAY BUFORD GA 30518
High Katherine A	director	3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104
Harrigan Edmund	director
Morrissey Michael James	officer: EVP, Head of Tech. Operations	IN CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803
Dickinson Jonathan Elliott	officer: EVP, General Manager, Europe	CARE OF INCYTE CORPORATION 1801 AUGUSTINE CUT OFF WILMINGTON DE 19803
Stamoulis Christiana	officer: EVP & Chief Financial Officer	C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST CAMBRIDGE MA 02139
Dhanak Dashyant	officer: EVP & Chief Scientific Officer	C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Pasquale Maria E	officer: EVP & General Counsel	C/O INCYTE CORPORATION 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Fouse Jacqualyn A	director	C/O DICK'S SPORTING GOODS 345 COURT STREET CORAOPOLIS PA 15108
Iyengar Vijay K	officer: EVP GPS, BD, & Licensing	1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Stein Steven H	officer: EVP & Chief Medical Officer	1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Trower Paul	officer: VP, Finance & Prin Acc Officer	1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Clancy Paul J	director	C/O BIOGEN IDEC INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142
Bienaime Jean Jacques	director	925 PAGE MILL ROAD PALO ALTO CA 94304